Appendix 4E and 2026 Annual Report
Filed with ASX · · 77 pages · English
Summary by 6ix AI
The report indicates a loss from ordinary activities after tax, with no dividends declared during the financial period. The company reported an increase in net assets, attributed to capital raisings that offset operating losses.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Prescient Therapeutics Limited on 6ix
Story so far
Earlier from Prescient Therapeutics
- June 2026 Quarterly Update and Appendix 4C
- March 2026 Quarterly Update and Appendix 4C
- Appendix 4D and Half Year Financial Report
- December 2025 Quarterly Update and Appendix 4C
- PTX secures EU Authorisation to commence PTX-100 Trial
Later from Prescient Therapeutics
- Prescient Therapeutics Opens SPP to Raise $7m Today
- PTX-100 CTCL Phase 2a study reaches review milestone
- PTX Successfully Completes $6m Raise Via SPP and Placement
- September 2026 Quarterly Update and Appendix 4C
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics